Company Overview and News

Warehouse Group ditches single-use plastic bags

The Warehouse Group is set to ditch all single-use plastic checkout bags and replace them with fully compostable bags.

NZX 50 charts record highs, led by Ryman, F&P Healthcare

New Zealand's benchmark stock index rose to a fresh record, led by retirement village operator Ryman Healthcare and Fisher & Paykel Healthcare Corp, while Pushpay fell.

Retail magnates the Normans increase stake in 'bland' underperforming The Warehouse

James Pascoe Group owners Anne and David Norman have lifted their stake in The Warehouse but analysts say it does not signal a takeover attempt - at least not yet.

Warehouse Group lifts third-quarter sales 2.6%

Warehouse Group's third-quarter sales advanced 2.6 per cent as its Noel Leeming appliance and technology chain outperformed its other businesses.

Commerce Commission takes Noel Leeming to court for allegedly misleading consumers

RELATED AUDIO: Consumer CEO Sue Chetwin on extended warranties — are they worth it? (Mar, 2016)

Noel Leeming stores accused of misleading customers

Electronic goods retailer Noel Leeming has been charged with misleading customers at eight of its stores.

Noel Leeming charged by ComCom over misleading consumers

"We're disappointed by the Commission's enforcement decision which came without the opportunity to investigate or discuss the complaints," a spokesperson for Noel Leeming said. "We take our compliance responsibilities seriously and we want to do the right thing by our customers. "As the matter is before the Court, we won't be making further comments."

Ethical fashion ranking: How New Zealand's largest retailers and brands fare

An advocate for ethical fashion retail says top brands are not doing enough to protect workers in their international supply chains despite attempts being made.

The rise of the cowboy toy importer: Do New Zealand's regulatory standards need a revamp?

Unsafe toys are being sold through discount stores, weekend market stalls and cowboy online sellers, putting young children at risk, says the head of New Zealand's largest toy distributor.

Jobs saved as plans to close Kaikohe Warehouse shelved

The Warehouse has backtracked on plans to close its Kaikohe store in Northland at the end of June, saving 33 permanent jobs.

Jobs saved as plans to close Kaikohe Warehouse shelved

The Warehouse has backtracked on plans to close its Kaikohe store in Northland at the end of June, saving 33 permanent jobs.

Dozens of jobs to go as Kaikohe Warehouse closes

The Warehouse says it's closing its Kaikohe store in Northland at the end of June, with 33 permanent jobs to go.

Shane Jones lashes out at 'anti-Kiwi companies' shunning Northland

"Anti-Kiwi" NZX companies are shunning Northland, according to Regional Development Minister Shane Jones, who says he's "had a gutsful" of businesses pulling out of places like Kaikohe.

The Warehouse to shut in Kaikohe by June: Shane Jones 'genuinely surprised'

National retailer The Warehouse told staff yesterday it was shutting its Kaikohe store because it has been unable to negotiate an extension of its lease on the premises and a union says 60 jobs will be lost.

Controversial data firm Cambridge Analytica linked with The Warehouse

The Warehouse Group has confirmed it has links with the data firm at the centre of an international scandal involving the misuse of Facebook users' personal information.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...